NAVER D2SF

Seoul – November 10, 2026 -- MOVIN, a LiDAR-based 3D motion data AI company backed by NAVER D2SF, has raised KRW 10 billion in a Series A round to expand from markerless motion capture into motion data infrastructure for physical AI.

IMM Investment led the round, with participation from Industrial Bank of Korea (IBK) and Voyager Ventures. Existing investors Atinum Investment, NAVER D2SF and Schmidt made follow-on investments. It is NAVER D2SF's third consecutive investment in the company, after a 2023 seed round and a 2025 pre-Series A round. That pre-Series A raised KRW 4 billion.

Seoul – September 20, 2026 -- NAVER D2SF, the in-house corporate venture arm of NAVER, has joined a $10 million Series A2 bridge round for Silicon Valley-based precision medicine company ImpriMed, backing its push toward U.S. regulatory clearance and Asian market expansion.

ImpriMed targets FDA clearance and CLIA certification by Q1 2027 for its blood cancer platform

The company is preparing to commercialize diagnostic products for blood cancers and blood infection in the United States, having already established business partnerships with major U.S. hospitals. ImpriMed's xCellSense platform keeps patient-derived cancer cells viable outside the body for extended periods, allowing evaluation of drug sensitivity alongside genomic, immunophenotypic and clinical data. The company's AI models are trained on more than 3.5 million data points combining real-world data with functional cell analysis.